Page 1548 - Williams Hematology ( PDFDrive )

1522 Part XI: Malignant Lymphoid Diseases Chapter 91: Acute Lymphoblastic Leukemia 1523

89. Pullarkat V, Slovak ML, Kopecky KJ, et al: Impact of cytogenetics on the outcome of 119. Mead GM, Barrans SL, Qian W, et al. for the UK National Cancer Research Institute
adult acute lymphoblastic leukemia: Results of Southwest Oncology Group 9400 study. Lymphoma Clinical Studies Group, Australasian Leukaemia and Lymphoma Group:
Blood 111:2563, 2008. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients
90. Ito C, Kumagai M, Manabe A, et al: Hyperdiploid acute lymphoblastic leukemia with 51 with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic
to 65 chromosomes: A distinct biological entity with a marked propensity to undergo criteria (MRC/NCRI LY10 trial). Blood 112:2248, 2008.
apoptosis. Blood 93:315, 1999. 120. Rizzieri DA, Johnson JL, Byrd JC, et al; Alliance for Clinical Trials In Oncology
91. Dastugue N, Suciu S, Plat G, et al: Hyperdiploidy with 58-66 chromosomes in child- (ACTION): Improved efficacy using rituximab and brief duration, high intensity che-
hood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. motherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and
Blood 121:2415, 2013. Leukemia Group B study 10002. Br J Haematol 165:102, 2014.
92. Nachman JB, Heerema NA, Sather H, et al: Outcome of treatment in children with 121. Schrappe M, Möricke A, Reiter A, et al: Key treatment questions in childhood acute
hypodiploid acute lymphoblastic leukemia. Blood 110:1112, 2007. lymphoblastic leukemia: Results in 5 consecutive trials performed by the ALL-BFM
93. Moorman AV, Richards SM, Robinson HM, et al: Prognosis of children with acute lym- study group from 1981 to 2000. Klin Padiatr 225 Suppl 1:S62, 2013.
phoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 122. Pui CH, Campana D: New definition of remission in childhood acute lymphoblastic
(iAMP21). Blood 109:2327, 2007. leukemia. Leukemia 14:783, 2000.
94. Harrison CJ, Moorman AV, Schwab C, et al: An international study of intrachromo- 123. Borowitz MJ, Devidas M, Hunger S, et al: Clinical significance of minimal residual dis-
somal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and ease in childhood acute lymphoblastic leukemia and its relationship to other prognostic
outcome. Leukemia 28:1015, 2014. factors: A Children’s Oncology Group study. Blood 111:5477, 2008.
95. Paulsson K, Horvat A, Strömbeck B, et al: Mutations in FLT3, NRAS, KRAS, and 124. Bruggemann M, Schrauder A, Raff R, et al; European Working Group for Adult Acute
PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood Lymphoblastic Leukemia (EWALL) and the International Berlin-Frankfurt-Munster
acute lymphoblastic leukemia. Genes Chromosomes Cancer 47:26, 2008. Study Group (I-BFM-SG), Standardized MRD quantification in European ALL trials:
96. Morely AA, Brisco MJ, Rice M, et al: Leukaemia presenting as marrow hypoplasia: Proceedings of the Second International Symposium on MRD assessment in Kiel, Ger-
Molecular detection of the leukaemic clone at the time of initial presentation. Br J Hae- many, 18-20 September 2008. Leukemia 24:521, 2010.
matol 98:940, 1997. 125. Schrappe M: Minimal residual disease: Optimal methods, timing, and clinical
97. McKenna RW, Washington LT, Aquino DB, et al: Immunophenotypic analysis of hema- relevance for an individual patient. Hematology Am Soc Hematol Educ Program
togones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 2012:137, 2012.
4-color flow cytometry. Blood 98:2498, 2001. 126. Gaipa G, Basso G, Biondi A, Campana D: Detection of minimal residual disease in
98. Coiffier B, Altman A, Pui CH, et al: Guidelines for the management of pediatric and pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom 84:359, 2013.
adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 26:2767, 2008. 127. Bassan R, Spinelli O, Oldani E, et al: Improved risk classification for risk-specific ther-
99. Masson E, Synold TW, Relling MV, et al: Allopurinol inhibits de novo purine synthesis apy based on the molecular study of minimal residual disease (MRD) in adult acute
in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia 10:56, 1996. lymphoblastic leukemia (ALL). Blood 113:4153, 2009.
100. Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel: Recommendations for the 128. Patel B, Rai L, Buck, et al: Minimal residual disease is a significant predictor of treat-
evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and chil- ment failure in non T-lineage adult acute lymphoblastic leukemia: Final results of the
dren with malignant diseases: An expert TLS panel consensus. Br J Haematol 149:578, international trial UKALL XII/ECOG 2993. Br J Haematol 148:80, 2010.
2010. 129. Beldjord K, Chevret S, Aasnafi V, et al; Group for Research on Adult Acute Lympho-
101. Pui CH, Boyett JM, Hughes WT, et al: Human granulocyte colony-stimulating factor blastic Leukemia (GRAALL): Oncogenetics and minimal residual disease are indepen-
after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J dent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood
Med 336:1781, 1997. 123:3739, 2014.
102. Larson RA, Dodge RK, Linker CA, et al: A randomized controlled trial of filgrastim 130. Annino L, Vegna ML, Camera A, et al: Treatment of adult acute lymphoblastic leuke-
during remission induction and consolidation chemotherapy for adults with acute lym- mia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood
phoblastic leukemia: CALGB study 9111. Blood 92:1556, 1998. 99:863, 2002.
103. Relling MV, Boyett JM, Blanco JG, et al: Granulocyte-colony stimulating factor and the 131. Stock W, Johnson JL, Stone RM, et al: Dose intensification of daunorubicin and cyta-
risk of secondary myeloid malignancy. Blood 101:3862, 2003. rabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and
104. Madden RM, Pui CH, Hughes WT, et al: Prophylaxis of Pneumocystis carinii pneumo- Leukemia Group B Study 19802. Cancer 119:90, 2013.
nia with atovaquone in children with leukemia. Cancer 109:1654, 2007. 132. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines
105. Heckman KD, Weiner GJ, Davis CS, et al: Randomized study of prophylactic plate- all prognostic factors in children and adolescents with B-cell precursor acute lympho-
let transfusion threshold during induction therapy for adult acute leukemia: 10,000/ blastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood
microL versus 20,000/microL. J Clin Oncol 15:1143, 1997. 115:3206, 2010.
106. Pieters R, Carroll WL: Biology and treatment of acute lymphoblastic leukemia. Hematol 133. Bostrom BC, Sensel MR, Sather HN, et al: Dexamethasone versus prednisone and daily
Oncol Clin North Am 24:1, 2010. oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lym-
107. Hunger, SP, Lu X, Devidas M, et al: Improved survival for children and adolescents with phoblastic leukemia: A report from the Children’s Cancer Group. Blood 101:3809, 2003.
acute lymphoblastic leukemia between 1990 and 2005: A report from the Children’s 134. Mitchell CD, Richards SM, Kinsey SE, et al: Benefit of dexamethasone compared with
Oncology Group. J Clin Oncol 29:551, 2011. prednisolone for childhood acute lymphoblastic leukaemia: Results of the UK Medical
108. Pui CH, Carroll WL, Meshinchi S, Arceci RJ: Biology, risk stratification, and therapy of Research Council ALL97 randomized trial. Br J Haematol 129:734, 2005.
pediatric acute leukemias: An update. J Clin Oncol 29:551, 2011. 135. Asselin BL, Whitin JC, Coppola DJ, et al: Comparative pharmacokinetic studies of three
109. Harrison CJ: Targeting signaling pathways in acute lymphoblastic leukemia: New asparaginase preparations. J Clin Oncol 11:1780, 1993.
insights. Hematology Am Soc Hematol Educ Program 2013:118, 2013. 136. Douer D, Yampolsky H, Cohen LJ, et al: Pharmacodynamics and safety of intravenous
110. Mann G, Attarbaschi A, Schrappe M, et al; Interfant-99 Study Group: Improved out- pegaspargase during remission induction in adults aged 55 years or younger with newly
come with hematopoietic stem cell transplantation in a poor prognostic subgroup of diagnosed acute lymphoblastic leukemia. Blood 1009:2744, 2007.
infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: 137. Vrooman LM, Stevenson KE, Supko JG, et al: Postinduction dexamethasone and indi-
Results from the Interfant-99 Study. Blood 116:2644, 2010. vidualized dosing of Escherichia coli l-asparaginase each improve outcome of children
111. Larson RA: Management of acute lymphoblastic leukemia in older patients. Semin and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a
Hematol 43:126, 2006. randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J
112. Gokbuget N: How I treat older patients with ALL. Blood 122:1366, 2013. Clin Oncol 31:1202, 2013.
113. Fielding AK: How I treat Philadelphia chromosome-positive acute lymphoblastic leu- 138. Wetzler M, Sanford BL, Kurtzberg J, et al: Effective asparagine depletion with pegy-
kemia. Blood 116:3409, 2010. lated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia:
114. Foa R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party: Dasatinib Cancer and Leukemia Group B Study 9511. Blood 109:4164, 2007.
as first-line treatment for adult patients with Philadelphia chromosome-positive acute 139. Douer D, Aldoss I, Lunning MA, et al: Pharmacokinetics-based integration of multiple
lymphoblastic leukemia. Blood 118:6521, 2011. doses of intravenous pegaspargase in a pediatric regimen for adults with newly diag-
115. Patte C, Auperin A, Michon J, et al: The Société Francaise d’Oncologie Pédiatrique nosed acute lymphoblastic leukemia. J Clin Oncol 32:905, 2014.
LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor bur- 140. Stock W, Douer D, DeAngelo DJ, et al: Prevention and management of asparaginase/
den and initial response in 561 unselected children with B-cell lymphomas and L3 leu- pegasparaginase-associated toxicities in adults and older adolescents: Recommenda-
kemia. Blood 97:3370, 2001. tions of an expert panel. Leuk Lymphoma 52:2237, 2011.
116. Cairo MS, Gerrard M, Sposto R, et al: Results of a randomized international study of 141. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lym-
high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic phoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy:
leukemia in children and adolescents. Blood 109:2736, 2007. Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood
117. Woessmann W, Seidemann K, Mann G, et al: The impact of the methotrexate admin- 95:3310, 2000.
istration schedule and dose in the treatment of children and adolescents with B-cell 142. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for
neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 105:948, 2005. children with high-risk acute lymphoblastic leukemia and a slow response to initial
118. Thomas DA, Faderl S, O’Brien S, et al: Chemoimmunotherapy with hyper-CVAD plus therapy. N Engl J Med 338:1663, 1998.
rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lym- 143. Chessells JM, Bailey C, Richards SM: Intensification of treatment and survival in all
phoblastic leukemia. Cancer 106:1569, 2006. children with lymphoblastic leukaemia: Results of UK Medical Research Council Trial

Kaushansky_chapter 91_p1505-1526.indd 1523 9/21/15 12:20 PM